Last reviewed · How we verify
Fluticasone/Azelastine nasal spray — Competitive Intelligence Brief
marketed
Intranasal corticosteroid/antihistamine combination
Glucocorticoid receptor; H1 histamine receptor
Allergy/Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Fluticasone/Azelastine nasal spray (Fluticasone/Azelastine nasal spray) — University of Chicago. Fluticasone/Azelastine combines a corticosteroid that reduces inflammation with an antihistamine that blocks allergic responses in the nasal passages.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluticasone/Azelastine nasal spray TARGET | Fluticasone/Azelastine nasal spray | University of Chicago | marketed | Intranasal corticosteroid/antihistamine combination | Glucocorticoid receptor; H1 histamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Intranasal corticosteroid/antihistamine combination class)
- University of Chicago · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluticasone/Azelastine nasal spray CI watch — RSS
- Fluticasone/Azelastine nasal spray CI watch — Atom
- Fluticasone/Azelastine nasal spray CI watch — JSON
- Fluticasone/Azelastine nasal spray alone — RSS
- Whole Intranasal corticosteroid/antihistamine combination class — RSS
Cite this brief
Drug Landscape (2026). Fluticasone/Azelastine nasal spray — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-azelastine-nasal-spray. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab